| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CMK | GDSC1000 | pan-cancer | AAC | -0.053 | 0.4 |
| mRNA | BRD-K28456706 | CTRPv2 | pan-cancer | AAC | -0.037 | 0.4 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | 0.036 | 0.4 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | -0.034 | 0.4 |
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.048 | 0.4 |
| mRNA | BRD-A86708339 | CTRPv2 | pan-cancer | AAC | 0.049 | 0.4 |
| mRNA | pac-1 | CTRPv2 | pan-cancer | AAC | 0.035 | 0.4 |
| mRNA | docetaxel:tanespimycin (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.032 | 0.4 |
| mRNA | RAF265 | FIMM | pan-cancer | AAC | -0.16 | 0.4 |
| mRNA | erastin | CTRPv2 | pan-cancer | AAC | -0.034 | 0.4 |